NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
NRBONeuroBo Pharmaceuticals(NRBO) Prnewswire·2024-06-22 20:01

DA-1726 Also Exhibited Superior Glucose Lowering Compared to SurvodutideLipid-Lowering Effect of DA-1726 Shown to be Superior Compared to TirzepatideData Presented at the ADA 84th Scientific SessionsCAMBRIDGE, Mass., June 22, 2024  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that fu ...